Researchers with two academic health systems recently tried a new approach to increase LDCT uptake, reaching patients electronically outside of a regular appointment and asking them to request a screening.
United Regional Health Care System recently announced the construction project’s kickoff, noting its desire to remain “responsive to the needs of our community.”
Up to 72% of CT requisitions from ED providers could be considered inadequate according to RI-RADS, which was developed to evaluate the clinical reasoning quality of imaging orders.
Beyond amyloidosis, nuclear cardiology is also increasingly used to image inflammation and infection in the myocardium, especially in diseases such as cardiac sarcoidosis and myocarditis.
The University of Pennsylvania in Philadelphia has aimed to tackle this conundrum, developing a deep learning-based image analysis tool and AI “orchestrator.”
Founded in 2019, Evergreen develops and manufactures imaging agents aimed at diagnosing and treating cancer, including Octevy for neuroendocrine tumors.
The bioresorbable agent is made from small irregularly shaped, dry gelatin particles designed for the embolization of hypervascular tumors and blood vessels.
Beyond amyloidosis, nuclear cardiology is also increasingly used to image inflammation and infection in the myocardium, especially in diseases such as cardiac sarcoidosis and myocarditis.
PET has already gained significant momentum in recent years. Now, researchers are pointing to another possible use for the popular imaging modality: assessing carotid artery atherosclerosis.
"PET has changed the practice of nuclear medicine in general and I think it is going to revitalize the practice of cardiology," Marcelo Di Carli, MD, told Cardiovascular Business. He noted that more practices seem interested in implementing PET than ever before.
